Polen Thomas E Jr sold $629K of BDX

Polen Thomas E Jr (Chairman, CEO and President) sold 2,993 shares of BECTON DICKINSON & CO (BDX) at $210.00 ($0.63M total) on 2026-11-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Polen Thomas E Jr
Published Nov 9, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BDX
Bearish
medium confidence
Mentioned
$BDX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDXBearishLow
01

Why it matters

The disclosed sale adds transparency but is unlikely to move the stock materially.

02

Market read

A modest insider sale; traders may note but not act on it.

03

What to watch

Potential upcoming earnings or product announcements may outweigh the sale's effect.

Relevance 4/10Novelty 3/10Timing: post‑market filing

Background

SEC Form 4 filing discloses an insider transaction by Becton Dickinson's CEO.

Company-level read

Ticker impact

$BDXBearishMedium confidence
Context

CEO Thomas E. Polen Jr sold 2,993 BDX shares for $628,530 via a 10b5‑1 plan, reducing his stake to 110,163 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sale

Evidence & confidence

A $628k sale by the CEO is a routine 10b5‑1 transaction; while not large, it signals potential insider sentiment and can prompt short‑term weakness.

Market effects

Minimal impact on the healthcare equipment sector.

No significant regional effect.

Limited to BDX investors.

Counterpoint

The sale could be a routine liquidity event and not indicative of negative outlook.

Key entities

  • Becton Dickinson & Co.

    Medical technology and device manufacturer.

  • Thomas E. Polen Jr

    Chairman, CEO and President of Becton Dickinson.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AAPLMed

New Australian Data Shed Even More Light on Tax Avoidance by Big Tech (and Others), Highlight Need for Better Disclosure in the U.S.

The Australian Taxation Office released country-by-country tax reports, revealing that Apple (25% of profits in Singapore) and Visa (62% of profits in Singapore) booked significant profits in low-tax jurisdictions. Becton Dickinson reported $266.2M pretax income in the Cayman Islands with no local employees. The data highlights discrepancies between U.S. and Australian disclosures, raising concerns about tax transparency.

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 Earnings Call Highlights

Becton, Dickinson (BDX) reported Q4 earnings, with revenue growth in Interventional (7.6%) and BioPharma Systems (7%). The company expects Q1 adjusted EPS of $2.32-$2.37, with full-year margins flat. BDX plans to discuss long-term targets on Dec. 10. Free cash flow rose 42% to $2.9B, with $3.6B returned to shareholders. BDX has a $19B U.S. investment agreement, potentially easing future tariffs.

$BDXHighAI 8/10

Becton Dickinson & Co (BDX) (Q4 2026) Earnings Call Highlights: Strong Q4 Beat, $19

Becton Dickinson (BDX) reported strong Q4 2026 results but issued cautious fiscal 2027 guidance, expecting low single-digit revenue growth due to a 200 basis point Alaris headwind. Adjusted operating margins are expected to remain flat, with inflation and investments offsetting productivity gains. The company's Q1 guidance is conservative, impacted by system cutovers and the Alaris comparison. Tariff relief benefits are not included in the guidance due to uncertainty.